DE69228813D1 - Verwendung von 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen - Google Patents

Verwendung von 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen

Info

Publication number
DE69228813D1
DE69228813D1 DE69228813T DE69228813T DE69228813D1 DE 69228813 D1 DE69228813 D1 DE 69228813D1 DE 69228813 T DE69228813 T DE 69228813T DE 69228813 T DE69228813 T DE 69228813T DE 69228813 D1 DE69228813 D1 DE 69228813D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
tyrosinemia
trifluormethylbenzoyl
cyclohexandion
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69228813T
Other languages
English (en)
Other versions
DE69228813T2 (de
DE122005000032I1 (de
DE122005000032I2 (de
Inventor
Martin Keith Ellis
Sven Torvald Lindstedt
Edward Alan Lock
Maj Elisabeth Holme Markstedt
Linda Carol Mutter
Michael Paul Prisbylla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919113622A external-priority patent/GB9113622D0/en
Priority claimed from GB929206412A external-priority patent/GB9206412D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of DE69228813D1 publication Critical patent/DE69228813D1/de
Publication of DE69228813T2 publication Critical patent/DE69228813T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Hydrogenated Pyridines (AREA)
DE69228813T 1991-06-24 1992-06-18 Verwendung von 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen Expired - Lifetime DE69228813T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919113622A GB9113622D0 (en) 1991-06-24 1991-06-24 Medicinal agents
GB929206412A GB9206412D0 (en) 1992-03-24 1992-03-24 Pharmaceutical compositions
PCT/GB1992/001094 WO1993000080A1 (en) 1991-06-24 1992-06-18 Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of tyrosinaemia and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69228813D1 true DE69228813D1 (de) 1999-05-06
DE69228813T2 DE69228813T2 (de) 1999-08-05

Family

ID=26299120

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1992628813 Active DE122005000032I2 (de) 1991-06-24 1992-06-18 Verwendung von 2-(2-Nitro-4-Trifluormethylbenzoyl)-1,3-Cyclohexandion zur Behandlung von Tyrosin{miesowie Pharmazeutische Zusammensetzungen
DE69228813T Expired - Lifetime DE69228813T2 (de) 1991-06-24 1992-06-18 Verwendung von 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1992628813 Active DE122005000032I2 (de) 1991-06-24 1992-06-18 Verwendung von 2-(2-Nitro-4-Trifluormethylbenzoyl)-1,3-Cyclohexandion zur Behandlung von Tyrosin{miesowie Pharmazeutische Zusammensetzungen

Country Status (17)

Country Link
US (1) US5550165A (de)
EP (1) EP0591275B1 (de)
JP (1) JP3130935B2 (de)
AT (1) ATE178207T1 (de)
AU (1) AU672361B2 (de)
CA (1) CA2072047C (de)
DE (2) DE122005000032I2 (de)
DK (1) DK0591275T3 (de)
ES (1) ES2129448T3 (de)
GR (1) GR3029841T3 (de)
HK (1) HK1008662A1 (de)
IE (1) IE922024A1 (de)
LU (1) LU91180I2 (de)
NL (1) NL300198I2 (de)
NO (3) NO304923B1 (de)
PT (1) PT100619B (de)
WO (1) WO1993000080A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4305696A1 (de) * 1993-02-25 1994-09-01 Hoechst Ag Nachweisverfahren zur Identifizierung von Inhibitoren
ATE276754T1 (de) * 1998-07-21 2004-10-15 Cytovia Inc Neue fluoreszensfarbstoffe und ihre anwendung in fluoreszensnachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
BRPI0621959A2 (pt) * 2006-08-18 2011-12-27 Syngenta Ltd usos de pelo menos um composto capaz de inibir 4-hidroxifenilpiruvato dioxigenase, e de um composto ou uma composiÇço, kit, e, composiÇço farmacÊutica
CN102711759B (zh) * 2010-01-29 2015-05-13 东丽株式会社 胆道疾病的治疗或预防药
EP2723320B1 (de) * 2011-06-23 2016-01-13 Swedish Orphan Biovitrum International AB Flüssige pharmazeutische zusammensetzung mit nitisinon
WO2013181292A1 (en) * 2012-05-29 2013-12-05 Biotie Therapies, Inc. Nitisinone formulations
CN102976948B (zh) * 2012-11-28 2014-07-09 郑州大明药物科技有限公司 尼替西农的制备方法
GB201400117D0 (en) * 2014-01-03 2014-02-19 Cycle Pharmaceuticals Ltd Pharmaceutical composition
ITUB20160650A1 (it) * 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
US9783485B1 (en) 2016-11-30 2017-10-10 Dipharma S.A. Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof
WO2024047657A1 (en) * 2022-08-28 2024-03-07 Brawn Laboratories Ltd Process for the preparation of nitisinone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780127A (en) * 1982-03-25 1988-10-25 Stauffer Chemical Company Certain 2-(substituted benzoyl)-1,3-cyclohexanediones and their use as herbicides
IL77349A (en) * 1984-12-20 1990-07-12 Stauffer Chemical Co 2-(2'-nitrobenzoyl)-1,3-cyclohexanediones,their preparation and their use as herbicides
US4774360A (en) * 1987-06-29 1988-09-27 Stauffer Chemical Company Converting enol ester precursor of a benzoyl-1,3-cycloalkyldione to a benzoyl-1,3-cycloalkyldione

Also Published As

Publication number Publication date
DE69228813T2 (de) 1999-08-05
NO934798L (no) 1993-12-23
DK0591275T3 (da) 1999-10-11
NL300198I2 (nl) 2005-09-01
AU672361B2 (en) 1996-10-03
NO304923B1 (no) 1999-03-08
CA2072047A1 (en) 1992-12-25
US5550165A (en) 1996-08-27
CA2072047C (en) 2003-06-10
JP3130935B2 (ja) 2001-01-31
EP0591275A1 (de) 1994-04-13
PT100619A (pt) 1994-01-31
AU1986092A (en) 1993-01-25
PT100619B (pt) 1999-07-30
NO2017045I1 (no) 2017-08-23
ES2129448T3 (es) 1999-06-16
NL300198I1 (nl) 2005-08-01
NO2005018I2 (no) 2008-02-11
NO934798D0 (no) 1993-12-23
NO2005018I1 (no) 2005-09-26
GR3029841T3 (en) 1999-07-30
HK1008662A1 (en) 1999-05-14
DE122005000032I1 (de) 2005-09-29
DE122005000032I2 (de) 2006-06-08
ATE178207T1 (de) 1999-04-15
EP0591275B1 (de) 1999-03-31
LU91180I2 (fr) 2005-09-06
IE922024A1 (en) 1992-12-30
WO1993000080A1 (en) 1993-01-07
JPH06508628A (ja) 1994-09-29

Similar Documents

Publication Publication Date Title
NO2017045I1 (no) Farmasøøytisk preparat inneholdende 2-(2-nitro-4-ifluormetylbenzoyl)-1,3-cykloheksandion eller et farmasøytisk godtagbart salt derav
UA39166C2 (uk) Похідні n-гідроксисечовини, що є інгібіторами ліпоксигенази у ссавців, спосіб їх одержання і спосіб інгібування ліпоксигенази у ссавців
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE59407237D1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
DE60330485D1 (de) Zur behandlung von diabetes
DE60207383D1 (de) Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
MX9300203A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
DE59101267D1 (de) N-Alkyl-N-(meth)acryloyloxyalkylcarboxamide aromatischer Carbonsäuren und aromatischer Carbonsäureanhydride sowie Adhäsive enthaltend diese Verbindungen.
ATE190484T1 (de) Arzneimittel zur behandlung von durch babesia verursachten protozoeninfektionen
DE69312297D1 (de) Verwendung von 2-[4-(-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinon zur behandlung von krebs
AP9701142A0 (en) 4,4-(Disubstituted) cyclohexan-1-ols monomers and related compounds.
ES2122005T3 (es) Medicamento que contiene (-)-metrifonato.
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
DE69715227D1 (de) Verwendung von kalzium dobesilat zur herstellung eines arzneimittels zur behandlung von embryonaler zurückgebliebenheit